Crosstalk between tumor necrosis factor-alpha signaling and aryl hydrocarbon receptor signaling in nuclear factor –kappa B activation: A possible molecular mechanism underlying the reduced efficacy of TNF-inhibitors in rheumatoid arthritis by smoking

Nii, Takuro; Kuzuya, Kentaro; Kabata, Daijiro; Matsui, Toshihiro; Murata, Atsuko; Ohya, Takeshi; Matsuoka, Hiroo; Shimizu, Takashi; Oguro, Eri; Okita, Yasutaka; Udagawa, Chikako; Yoshimura, Maiko; Kudo-Tanaka, Eriko; Teshigawara, S.; Harada, Yoshinori; Yoshida, Yūji; Isoda, Kentaro; Tsuji, Shujiro; Ohshima, Shiro; Hashimoto, Jun; Shintani, Ayumi; Takehana, Yasuo; Tohma, Shigeto; Saeki, Yukihiko

doi:10.1016/j.jaut.2018.12.004

Cited by 16 publications

(9 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, cigarette smoking markedly induces inflammation and alters immune signaling pathways. Studies have shown that smoking can promote the body's inflammatory response by increasing the release of pro-inflammatory factors [42][43][44] . In addition, smoking leads to oxidative stress, which induces systemic inflammation.…”

Section: Discussionmentioning

confidence: 99%

Association between smoking and risk of death in patients with sepsis: A systematic review and meta-analysis

Zhang¹,

Liu²,

Yang³

et al. 2022

Tob. Induc. Dis.

View full text Add to dashboard Cite

INTRODUCTION Although some research papers have suggested that smoking may increase mortality in patients with sepsis, no evidence has been produced in this regard. This systematic research evaluated the risk of death in patients with sepsis who were smokers to facilitate better clinical decision making. METHODS This is a systematic review registered in PROPERO (CRD42022296654). Searches were conducted to identify suitable studies from the databases of PubMed, Embase, Web of Science and the Cochrane Controlled Register of Trials from January 1980 to June 2021. Two independent reviewers screened the articles using keywords and extracted the data. The Newcastle–Ottawa Scale (NOS) was used to evaluate the quality of evidence. The primary endpoints included the mortality of patients with sepsis. RESULTS Five studies involving 2694 participants were included in our study. Among the five included articles, three studies had an NOS score of 6, while the other two had an NOS score of 7. The results showed that a significantly higher risk of death was observed in smokers with sepsis compared with non-smokers with sepsis (hazard ratio, HR=1.62; 95% CI: 1.11–2.37, p=0.01). Among the patients followed for more than 2 months, the mortality rate of smokers was significantly higher (2.33 times) than that of non-smokers (HR=2.33; 95% CI: 1.83–2.96, p<0.01). The difference in mortality did not reach statistical significance when the follow-up period was shorter than 2 months (HR=1.22; 95% CI: 0.96–1.56, p=0.10). CONCLUSIONS Smoking increased mortality in patients with sepsis when the follow-up period was longer than 2 months.

show abstract

Section: Discussionmentioning

confidence: 99%

Association between smoking and risk of death in patients with sepsis: A systematic review and meta-analysis

Zhang¹,

Liu²,

Yang³

et al. 2022

Tob. Induc. Dis.

View full text Add to dashboard Cite

show abstract

“…for the exacerbation of RA in cigarette smokers (20)(21)(22). Indeed, activation of AHRs by the constituents of cigarette smoke can potentiate the induction of NFkB by Tumor Necrosis Factor-α (TNF-α), leading not only to increased inflammatory activity but also reducing the efficacy of anti-TNF-α medications and possibly explaining both the apparent resistance of some patients to these drugs but also the high rate of non-compliance or discontinuation (23). The mechanism of AHR in these cases is likely to involve changes in the number and activity of Th17 cells (21) consistent with the evidence noted above.…”

Section: Rheumatoid Arthritismentioning

confidence: 99%

IDO and Kynurenine Metabolites in Peripheral and CNS Disorders

et al. 2020

View full text Add to dashboard Cite

The importance of the kynurenine pathway in normal immune system function has led to an appreciation of its possible contribution to autoimmune disorders such as rheumatoid arthritis. Indoleamine-2,3-dioxygenase (IDO) activity exerts a protective function, limiting the severity of experimental arthritis, whereas deletion or inhibition exacerbates the symptoms. Other chronic disorder with an inflammatory component, such as atherosclerosis, are also suppressed by IDO activity. It is suggested that this overall anti-inflammatory activity is mediated by a change in the relative production or activity of Th17 and regulatory T cell populations. Kynurenines may play an anti-inflammatory role also in CNS disorders such as Huntington's disease, Alzheimer's disease and multiple sclerosis, in which signs of inflammation and neurodegeneration are involved. The possibility is discussed that in Huntington's disease kynurenines interact with other anti-inflammatory molecules such as Human Lymphocyte Antigen-G which may be relevant in other disorders. Kynurenine involvement may account for the protection afforded to animals with cerebral malaria and trypanosomiasis when they are treated with an inhibitor of kynurenine-3-monoxygenase (KMO). There is some evidence that changes in IL-10 may contribute to this protection and the relationship between kynurenines and IL-10 in arthritis and other inflammatory conditions should be explored. In addition, metabolites of kynurenine downstream of KMO, such as anthranilic acid and 3-hydroxy-anthranilic acid can influence inflammation, and the ratio of these compounds is a valuable biomarker of inflammatory status although the underlying molecular mechanisms of the changes require clarification. Hence it is essential that more effort be expended to identify their sites of action as potential targets for drug development. Finally, we discuss increasing awareness of the epigenetic regulation of IDO, for example by DNA methylation, a phenomenon which may explain differences between individuals in their susceptibility to arthritis and other inflammatory disorders.

show abstract

“…However, it is still challenging to understand whether or how smoking work together with TNF blockade to orchestrate the psoriasis occurrence. In vitro , cigarette smoke chemical components could activate nuclear factor kappa-B activation and proinflammatory cytokine production, including IL-1β and IL-6 ( 50 ). The full blockade of TNF-α may impair the homeostasis of normal skin and cause an imbalance in cytokines and cells, which may be further exacerbated by the presence of smoking, and finally paradoxical adverse events occur ( 50 ).…”

Section: Discussionmentioning

confidence: 99%

“…In vitro , cigarette smoke chemical components could activate nuclear factor kappa-B activation and proinflammatory cytokine production, including IL-1β and IL-6 ( 50 ). The full blockade of TNF-α may impair the homeostasis of normal skin and cause an imbalance in cytokines and cells, which may be further exacerbated by the presence of smoking, and finally paradoxical adverse events occur ( 50 ). For paradoxical skin inflammation, the IFN-α pathway was considered to play a key role.…”

Section: Discussionmentioning

confidence: 99%

Incidence of and Risk Factors for Paradoxical Psoriasis or Psoriasiform Lesions in Inflammatory Bowel Disease Patients Receiving Anti-TNF Therapy: Systematic Review With Meta-Analysis

2022

View full text Add to dashboard Cite

BackgroundParadoxical psoriasis or psoriasiform lesions induced by anti-tumor necrosis factor (anti-TNF) therapies receive increasing attention worldwide. However, no comprehensive meta-analysis investigating the incidence estimates and risk factors for anti-TNF-induced psoriasis is currently available. We aimed to precisely quantify its incidence as well as risk factors in patients with inflammatory bowel disease (IBD).MethodsThis study was registered on PROSPERO database under review registration number CRD42021233695. The electronic databases PubMed, EMBASE, and the Cochrane library were comprehensively searched for observational studies published as full-length papers in English and reporting the incidence and/or predictors for psoriasis or psoriasiform lesions in IBD patients. A random-effects meta-analysis was performed to calculate the pooled incidence. Pooled odds ratio (OR) and 95% confidence interval for potential predictors were combined using a fixed-effects or random-effects model.ResultsIn total, 30 articles comprising 24,547 IBD patients treated by anti-TNF were finally included. The overall pooled incidence of psoriasis and/or psoriasiform lesions following anti-TNF therapy was 6.0% (5.0–7.0%; I2 = 93.9%), with 6.9% (5.1–8.7%; I2 = 92.4%) for psoriasiform lesions and 4.6% (3.6–5.6%; I2 = 93.9%) for psoriasis. Multivariable meta-regression analysis indicated regions and populations that significantly contributed to the heterogeneity. A statistically higher risk for psoriasis or psoriasiform lesions during anti-TNF therapy was observed in female patients (OR 1.46, 1.23–1.73), those who are at a younger age at anti-TNF initiation (OR 1.03, 1.00–1.05), smokers (OR 1.97, 1.56–2.48), ileocolonic Crohn’s disease patients (OR 1.48, 1.03–2.13), and those who are using adalimumab or certolizumab (vs. infliximab) (OR: 1.48 and 2.87 respectively).ConclusionsThe incidence of psoriasis or psoriasiform lesions was not uncommon in IBD patients following anti-TNF therapy. Female, younger age, smoker, ileocolonic Crohn’s disease, and the types of anti-TNF were significantly associated with such risk. These findings may help gastroenterologists to make more individualized decisions and understand the mechanisms of this paradoxical phenomenon.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=233695, identifier CRD42021233695.

show abstract

Crosstalk between tumor necrosis factor-alpha signaling and aryl hydrocarbon receptor signaling in nuclear factor –kappa B activation: A possible molecular mechanism underlying the reduced efficacy of TNF-inhibitors in rheumatoid arthritis by smoking

Cited by 16 publications

References 49 publications

Association between smoking and risk of death in patients with sepsis: A systematic review and meta-analysis

Association between smoking and risk of death in patients with sepsis: A systematic review and meta-analysis

IDO and Kynurenine Metabolites in Peripheral and CNS Disorders

Incidence of and Risk Factors for Paradoxical Psoriasis or Psoriasiform Lesions in Inflammatory Bowel Disease Patients Receiving Anti-TNF Therapy: Systematic Review With Meta-Analysis

Contact Info

Product

Resources

About